Hans Hogerzeil
Biographic Data
| ID | 9798789 |
|---|---|
| NAME | Hans Hogerzeil |
| GIVEN NAMES | Hans |
| FAMILY NAME | Hogerzeil |
| SIGNATURE | HOGERZEIL H |
| AFFILIATIONS | University Medical Center Groningen |
| VERIFIED | No |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 1 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2026 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Weak economic evidence for WHO’s essential cancer medicines for Africa
INTRODUCTION: The WHO Model Lists of Essential Medicines (MLEM and MLEMc) guide national medicine selection, particularly in low-income and lower middle-income countries (LMICs). Concerns exist about the adequacy and transferability of economic evidence supporting recent cancer medicine additions. METHODS: We systematically examined modifications to cancer medicines on the WHO MLEM(c) between 2017 and 2023 and assessed their adoption into Nationa…
No prominent works on this page.
Weak economic evidence for WHO’s essential cancer medicines for Africa
INTRODUCTION: The WHO Model Lists of Essential Medicines (MLEM and MLEMc) guide national medicine selection, particularly in low-income and lower middle-income countries (LMICs). Concerns exist about the adequacy and transferability of economic evidence supporting recent cancer medicine additions. METHODS: We systematically examined modifications to cancer medicines on the WHO MLEM(c) between 2017 and 2023 and assessed their adoption into Nationa…
Access to medicines (1 works) · Alternative medicine (1 works) · Cancer (1 works) · Essential medicines (1 works) · Evidence-based medicine (1 works) · Evidence-based policy (1 works) · Health Systems, Economic Evaluations, Quality of Life (1 works) · Pharmaceutical Economics and Policy (1 works) · Pharmaceutical studies and practices (1 works) · Sustainability (1 works)